Skip to content

Study · Randomized controlled trial · n = 341 · 2021

3 results

Tesamorelin improves fat quality independent of changes in fat quantity.

Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT

AIDS (London, England)1 Jul 2021Cited by 6 (Europe PMC)

PMID33756511 (opens in a new tab)PMCIDPMC8243807 (opens in a new tab)DOI10.1097/qad.0000000000002897 (opens in a new tab)PepBankPUB-33756511
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with HIV and central adiposity, tesamorelin responders had a greater increase in visceral fat density than placebo over 26 weeks.

    In plain wordsIn people with HIV and central fat, visceral fat density rose more in tesamorelin responders than with placebo, a sign of higher fat quality.

    Peptide
    Tesamorelin
    Outcome
    IncreaseVisceral adipose tissue density change
    Study

    n = 341

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    VAT density change
    6.2 HU
    tesamorelin responders
    VAT density change
    0.3 HU
    placebo

    Source sentences

    Summary
    Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 (8.7) HU tesamorelin, +0.3 (4.2) HU placebo, P < 0.0001; SAT: +4.0 (8.7) HU tesamorelin, +0.3 (4.8) HU placebo, P < 0.0001].
    1 context sentence
    Summary · context
    Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PWH were included if they had either a clinical response to tesamorelin (VAT decrease ≥8%, ≈70% of participants) or were placebo-treated.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with HIV and central adiposity, tesamorelin responders had a greater increase in subcutaneous fat density than placebo over 26 weeks.

    In plain wordsIn people with HIV and central fat, under-skin fat density rose more in tesamorelin responders than with placebo, a sign of higher fat quality.

    Peptide
    Tesamorelin
    Outcome
    IncreaseSubcutaneous adipose tissue density change
    Study

    n = 341

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    SAT density change
    4 HU
    tesamorelin responders
    SAT density change
    0.3 HU
    placebo

    Source sentences

    Summary
    Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 (8.7) HU tesamorelin, +0.3 (4.2) HU placebo, P < 0.0001; SAT: +4.0 (8.7) HU tesamorelin, +0.3 (4.8) HU placebo, P < 0.0001].
    1 context sentence
    Summary · context
    Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PWH were included if they had either a clinical response to tesamorelin (VAT decrease ≥8%, ≈70% of participants) or were placebo-treated.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with HIV and central adiposity who responded to tesamorelin, the greater rise in VAT and SAT density than with placebo persisted after controlling for baseline density and area and for area change.

    In plain wordsIn people with HIV who responded to tesamorelin, fat density rose more than with placebo, even after accounting for other fat measures.

    Peptide
    Tesamorelin
    Outcome
    IncreaseVAT and SAT density change after adjustment
    Study

    n = 341

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The tesamorelin effects persisted after controlling for baseline VAT or SAT HU and area, and VAT [+2.3 HU, 95% confidence interval (4.5-7.3), P = 0.001) or SAT (+3.5 HU, 95% confidence interval (2.3-4.7), P < 0.001] area change.
    1 context sentence
    Summary · context
    Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PWH were included if they had either a clinical response to tesamorelin (VAT decrease ≥8%, ≈70% of participants) or were placebo-treated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.